Atlanta Consulting Group Advisors’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.23M Buy
40,446
+35,025
+646% +$4.1M 0.83% 22
2026
Q1
$657K Buy
5,421
+160
+3% +$18.5K 0.14% 81
2025
Q4
$557K Buy
5,261
+14
+0.3% +$1.31K 0.13% 86
2025
Q3
$445K Sell
5,247
-119
-2% -$9.8K 0.11% 88
2025
Q2
$429K Sell
5,366
-3,930
-42% -$312K 0.12% 80
2025
Q1
$842K Sell
9,296
-1,434
-13% -$134K 0.25% 51
2024
Q4
$1.07M Buy
10,730
+258
+2% +$26.6K 0.39% 43
2024
Q3
$1.19M Buy
10,472
+440
+4% +$52.3K 0.3% 67
2024
Q2
$1.24M Sell
10,032
-50
-0.5% -$6.44K 0.27% 39
2024
Q1
$1.33M Buy
+10,082
New +$1.24M 0.46% 35

Other funds holding MRK

Atlanta Consulting Group Advisors's MRK Position: Q2 2026 in Review

Atlanta Consulting Group Advisors increased its Merck (MRK) stake by 646% in Q2 2026, buying an estimated $4.1M and bringing the position to 40,446 shares worth $5.23M. The position accounts for 0.83% of the portfolio, ranked #22.

Atlanta Consulting Group Advisors first reported a position in MRK in Q1 2024 and has held it in 10 quarters since. 3,852 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Atlanta Consulting Group Advisors held 40,446 shares of Merck worth $5.23M as of Q2 2026.
  • Atlanta Consulting Group Advisors bought 35,025 Merck shares in Q2 2026, an estimated $4.1M.
  • Merck made up 0.83% of Atlanta Consulting Group Advisors's portfolio in Q2 2026, its #22 holding.
  • Atlanta Consulting Group Advisors first reported a position in Merck in Q1 2024 and has held it in 10 quarters since.
  • 3,852 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Atlanta Consulting Group Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.